Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Department of Medicine, University of Calgary, Calgary, AB, Canada Community Health Sciences, Institute of Public Health, University of Calgary, Calgary, AB, Canada Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada.
Nephrol Dial Transplant. 2014 Sep;29(9):1778-86. doi: 10.1093/ndt/gfu205. Epub 2014 Jun 3.
People with kidney allograft failure represent an increasing fraction of all those starting dialysis therapy. We sought to summarize prognosis following kidney allograft failure and identify potentially beneficial interventions or modifiable risk factors.
We searched MEDLINE and EMBASE (inception to 1 October 2013) and article reference lists without language restriction and selected cohort studies of all-cause mortality and fatal infection-related and cardiovascular events in people starting dialysis following kidney allograft failure. Two reviewers independently extracted data on study design, participant characteristics, dialysis modality, transplant nephrectomy, immunosuppression strategy, transplant-naive comparators and risk of bias. Discrepancies were resolved with a third reviewer.
Forty studies comprising 249 716 participants met the inclusion criteria. The first year of dialysis therapy was associated with the highest mortality. By random effects meta-analysis, annual risk of death, from years 1 to 4, was 0.12 [95% confidence interval (95% CI): 0.09-0.15], 0.06 (95% CI: 0.05-0.07), 0.05 (95% CI: 0.04-0.06) and 0.05 (95% CI: 0.04-0.06), respectively. We found high heterogeneity in each meta-analysis, which remained unexplained by prespecified subgroup analyses. We could not find sufficient information to summarize the risk for fatal infection-related and cardiovascular events, or to test the role of transplant nephrectomy or different immunosuppressive strategies. Risk of bias was high, especially participation bias.
Mortality is higher during the first year of dialysis treatment following kidney allograft failure than in subsequent years. Insufficient data are available to assess factors or interventions potentially impacting prognosis following kidney allograft failure. In a culture promoting transplantation, clinical research of different models of care in this growing high-risk population should be a research priority.
肾移植失败的患者在开始透析治疗的人群中所占比例不断增加。我们试图总结肾移植失败后的预后,并确定潜在有益的干预措施或可改变的危险因素。
我们检索了 MEDLINE 和 EMBASE(从建库起到 2013 年 10 月 1 日),并对文献进行了无语言限制的筛选,纳入了所有关于肾移植失败后开始透析治疗的患者的全因死亡率、与致死性感染相关的心血管事件和心血管事件的队列研究。两名审查员独立提取了研究设计、参与者特征、透析方式、移植肾切除术、免疫抑制策略、移植初治对照组和偏倚风险的数据。如有分歧,由第三名审查员解决。
40 项研究共纳入 249716 名参与者,符合纳入标准。透析治疗的第一年死亡率最高。通过随机效应荟萃分析,第 1 至第 4 年的年死亡率分别为 0.12(95%可信区间[95%CI]:0.09-0.15)、0.06(95%CI:0.05-0.07)、0.05(95%CI:0.04-0.06)和 0.05(95%CI:0.04-0.06)。我们发现每次荟萃分析的异质性都很高,预先设定的亚组分析无法解释这种异质性。我们没有找到足够的信息来总结与致死性感染相关的心血管事件的风险,也无法检验移植肾切除术或不同免疫抑制策略的作用。偏倚风险很高,特别是参与偏倚。
肾移植失败后开始透析治疗的第一年死亡率高于随后几年。目前尚无足够的资料评估潜在影响肾移植失败后预后的因素或干预措施。在一个提倡移植的文化中,应该将对这个高风险人群中不同护理模式的临床研究作为研究重点。